The efficacy of azithromycin in the treatment of acute infraorbital space infection

Journal of Oral and Maxillofacial Surgery

Volumn 61, Issue 3, 2003, Pages 310-316

  Al Belasy, Fouad A ^a   Hairam, Ashraf R ^a  

^a Mansoura University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; PLACEBO;

ACUTE DISEASE; ADJUVANT THERAPY; ADULT; ANTIMICROBIAL ACTIVITY; ARTICLE; BLOOD PLACENTA BARRIER; CERVICAL LYMPH NODE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEAD AND NECK INFECTION; HOSPITAL ADMISSION; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PENICILLIN ALLERGY; RANDOMIZED CONTROLLED TRIAL; SURGICAL DRAINAGE; TOOTH INFECTION;

EID: 0037372919     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1053/joms.2003.50063     Document Type: Article

References (62)

1. Roy KM, Bagg J: Antibiotic prescribing by general dental practitioners in the Greater Glasgow Health Board, Scotland. Br Dent J 188:476, 2000
2. Lewis MAO, McGowan DA, MacFarlane TW: Short-course highdose amoxycillin in the treatment of acute dentoalveolar abscess. Br Dent J 161:299, 1986
3. Peterson LJ: Principles of antibiotic therapy, in Topazian RG, Goldberg MH (eds): Oral and Maxillofacial Infections (ed 2). Philadelphia, PA, Saunders, 1987, pp 123-125
4. Sandor GK, Low DE, Judd PL, et al: Antimicrobial treatment options in the management of odontogenic infections. J Can Dent Assoc 64:508, 1998
5. Lewis MAO, Meechan C, MacFarlane TW, et al: Presentation and antimicrobial treatment of acute orofacial infections in general dental practice. Br Dent J 166:41, 1989
6. Palmer NAO, Pealing R, Ireland RS, et al: A study of therapeutic antibiotic prescribing in National Health Service general dental practice in England. Br Dent J 188:554, 2000
7. Guralnick W: Odontogenic infections. Br Dent J 156:440, 1984
8. Dajani AS, Taubert KA, Wilson W, et al: Prevention of bacterial endocarditis: Recommendations by the American Heart Association. J Am Dental Assoc 128:1142, 1997
9. Moore PA: Dental therapeutic indications for the newer long-acting macrolide antibiotics. J Am Dental Assoc 130:1341, 1999
10. Retsema J, Girard A, Schelkly W, et al: Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 31:1939, 1987
11. Washington JA, Wilson WR: Erythromycin: A microbial and clinical perspective after 30 years of clinical use. Mayo Clin Proc 60:189, 1985
12. Wilson JT, van Boxtel CJ: Pharmacokinetics of erythromycin in man. Antibiot Chemother 25:181, 1978
13. Finegold SM: Antimicrobial therapy of anaerobic infections: A status report. Hosp Pract 14:71, 1979
14. Griffith RS, Black HR: Erythromycin. Med Clin North Am 54: 1199, 1970
15. Philipson A, Sabath LD, Charles D: Transplacental passage of erythromycin and clindamycin. N Engl J Med 288:1219, 1973
16. Brun Y, Forey F, Gamondes JP, et al: Levels of erythromycin in pulmonary tissue and bronchial mucus compared to those of amoxicillin. J Antimicrob Chemother 8:459, 1981
17. Falchi M, Teodori F, et al: Penetration of erythromycin into tonsillar tissue. Curr Med Res Opin 9:611, 1985
18. Carlier MB, Zenebergh A, Tulkens PM: Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother 20:47, 1987 (suppl B)
19. Martin JR, Johnson P, Miller MF: Uptake, accumulation and egress of erythromycin by tissue culture cells of human origin. Antimicrob Agents Chemother 27:314, 1985
20. Chun AHC, Seitz JA: Pharmacokinetics and biological availability of erythromycin. Infection 5:14, 1977 (suppl 1)
21. Abbott Laboratories: Erythromycin. A Review of Its Properties and Clinical Status. Chicago, IL, Abbott Laboratories, Scientific Divisions North, 1966
22. Seifert CF, Swaney RJ, Bellanger-McCleery RA: Intravenous erythromycin lactobionate-induced severe nausea and vomiting. Drug Intell Clin Pharm 23:40, 1989
23. Braun P: Hepatotoxicity of erythromycin (editorial). J Infect Dis 119:300, 1969.
24. Tolman KG, Sannella JJ, Freston JW: Chemical structure of erythromycin and hepatotoxicity. Ann Intern Med 81:58, 1974
25. Ludden TM: Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 10:63, 1985
26. Honig PK, Woosley RI, Zamani K, et al: Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 52:231, 1992
27. Michalets EL: Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 18:84, 1998
28. Maxwell DL, Gilmour-White SK, Hall MR: Digoxin toxicity due to interaction of digoxin with erythromycin. Br Med J 298:572, 1989
29. Martell R, Heinrichs D, Stiller CR, et al: The effects of erythromycin in patients treated with cyclosporine. Ann Intern Med 104:660, 1986
30. Bartle WP: Possible warfarin-erythromycin interaction. Arch Intern Med 140:985, 1980
31. Olkkola KT, Aranko K, Luurila H, et al: A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298, 1993
32. Bright GM, Nagel AA, Bordner J, et al: Synthesis, in vitro and in-vivo activity of novel 9-deoxo-9a-aza-9a homoerythromycin A derivatives; a new class of macrolide antibiotics, the azalides. J Antibiot 41:1029, 1988
33. Fiese FF, Steffen SH: Comparison of the acid stability of azithromycin and erythromycin A. J Antimicrob Chemother 25:39, 1990 (suppl A)
34. Girard AE, Girard D, English AE, et al: Pharmacokinetic and in-vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother 31:1948, 1987
35. Foulds G, Shepard RM, Johnson RB: The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25:73, 1990 (suppl A)
36. Gladue RP, Bright GM, Isaacson RI, et al: In-vitro and in-vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at site of infection. Antimicrob Agents Chemother 33:277, 1989
37. Peters DH, Fridel HA, McTavish D: Azithromycin: A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44:750, 1992
38. Clarithromycin and azithromycin. Med Lett 34:45, 1992
39. Amsden GW: Macrolides versus azalides: A drug interaction update. Ann Pharmacother 29:906, 1995
40. Mattila MJ, Vanakoski J, Idanpaan-Heikkila JJ: Azithromycin does not alter the effects of oral midazolam on human performance. Eurj Clin Pharmacol 47:49, 1994
41. Laskin DM, Laskin JL: Odontogenic infections of the head and neck, in Laskin DM: Oral and Maxillofacial Surgery, vol 2. St Louis, MO, CV Mosby, 1985, p 219
42. Martin MV, Longman LP, Hill JB, et al: Acute dentoalveolar infections: An investigation of the duration of antibiotic therapy. Br Dent J 183:135, 1997
43. Zakrzewska JM, Feinmann C: A standard way to measure pain and psychological morbidity in dental practice. Br Dent J 169: 337, 1990
44. Trumpy IG, Lyberg T: Surgical treatment Of internal derangement of the temporomandibular joint: Long-term evaluation of three techniques. J Oral Maxillofac Surg 53:740, 1995
45. Berge IT: Visual analogue scale assessment of postoperative swelling. Acta Odontol Scand 46:233, 1988
46. Davis WM, Balcom JH: Lincomycin studies of drug absorption and efficacy. Oral Surg 27:688, 1969
47. Schuen NJ, Panzer JD, Atkinson WH: A comparison of clindamycin and penicillin in the treatment of oral infections. J Oral Surg 32:503, 1974
48. Breytenbach HS: Objective measurement of postoperative swelling. Int J Oral Surg 7:386, 1978
49. Pedersen A, Moller MO: Volumetric determination of extraoral swelling from stereophotographs. J Oral Surg 14:229, 1985
50. Schultze-Mosgau S, Schmelzeisen R, Frolich JC, et al: Use of ibuprofen and methylprednisolone for the prevention of pain and swelling after removal of impacted third molars. J Oral Maxillofac Surg 53:2, 1995
51. Muthukrishnan A, Walters H, Douglas PS: An audit of antibiotic prescribing by general practitioners in the initial management of acute dental infections. Dental Update 33:316, 1996
52. Steed M, Gibson J: An audit of antibiotic prescribing in general dental practice. Prim Dent Care 4:66, 1997
53. Zerr MA, Walton R, Peterson L: Antibiotics: Indications, contraindications, and non-indications. Northwest Dent 77:19, 1998
54. Palmer NOA, Martin MV: An investigation of antibiotic prescribing by general dental practitioners: A pilot study. Prim Dent Care 5:11, 1998
55. Epstein JB, Chong S, Le ND: A survey of antibiotic use in dentistry. J Am Dental Assoc 131:1600, 2000
56. Longman LP, Martin MV: The use of antibiotics in the prevention of postoperative infection: A reappraisal. Br Dent J 170: 257, 1991
57. Lacy RW, Lord VL, Howson GL, et al: Double-blind study to compare the selection of antibiotic resistance by amoxycillin or cephradine in the commensal flora. Lancet 2:529, 1983
58. Guillemot D, Carbon C, Vauzellkervroedan F, et al: Inappropriateness and variability of antibiotic prescription among French office-based physicians. J Clin Epidemiol 51:61, 1998
59. Lacy RW: Evolution of microorganisms and antibiotic resistance. Lancet 2:1022, 1984
60. Fazakerley MW, McGowan P, Hardy P, et al: A comparative study of cephradine, amoxycillin, and phenoxymethylpenicillin in the treatment of acute dentoalveolar infections. Br Dent J 174:359, 1993
61. Shepard RM, Falkner FC: Pharmacokinetics of azithromycin in rats and dogs. J Antimicrob Chemother 25:49, 1990 (suppl A)
62. Girard AE, Girard D, Retsema JA: Correlation of the extravascular pharmacokinetics of azithromycin with in-vivo efficacy in models of localized infection. J Antimicrob Chemother 25:61, 1990 (suppl A)